CClinicalTrials.gg
Sign In
RecruitingNCT06275334DNBUpdated Feb 23, 2024

Dinutuximab Beta at the HUS and the Toulouse Oncopole

An observational study in Neuroblastoma, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 10 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
40
Ages
2 Years to 25 Years
Sex
All
01

Study summary

In this study the investigators wish to describe the cohort of pediatric patients suffering from neuroblastoma and treated with Dinutuximab and to compare the costs and quality of life between the two French centers, the University Hospital of Strasbourg (HUS) and the Oncopole of Toulouse.

02

Conditions studied

  • Neuroblastoma

Browse trials for

Keywords

  • Neuroblastoma
  • Dinutuximab Beta
  • DNB
03

In context

Neuroblastoma

625 studies on the registry are indexed under Neuroblastoma; 122 are open to participants now.

This study's planned enrollment of 40 is below the median of 121 across 77 observational studies indexed under Neuroblastoma.

Browse Neuroblastoma studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Subjects aged 2 years to 25 years suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023.

Inclusion criteria

  • Subjects aged 2 years to 25 years
  • Male or female gender
  • Subjects suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023.
  • Subject (and/or holders of parental authority) not opposing, after information, the reuse of the child's data for the purposes of this research and agreeing to respond to the quality of life survey.

Exclusion criteria

Exclusion Criteria:

  • Patient or parents of the minor having expressed their opposition to participating in the study.
  • specific clinical forms of the disease,
  • interfering treatments and associated diseases.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Comparison of two methods of treating a pediatric pathology in two French health establishments, the HUS and the Oncopole of Toulouse.

    This study is retrospective and consists of comparing two methods of treating neuroblastoma in two health establishments and covers the period from January 1, 1998 to December 31, 2023.

    Time frame: The period concerned is from January 1, 1998 to December 31, 2023.

07

Study locations

1 of 1 sites recruiting
  • Service de Pharmacie - Stérilisation - CHU de Strasbourg - France
    Strasbourg, 67091, France
    • Anne EL AATMANI, Pharm, PhD · Contact · Anne.ELAATMANI@chru-strasbourg.fr · 33 3 88 12 78 06
    • Emilie BERTHON, Pharm, PhD · Contact · emilieberthon@orange.fr · 33 3 88 12 78 06
    • Anne EL AATMANI, Pharm, PhD · Principal investigator
    • Emilie BERTHON, PhamD, PhD · Principal investigator
    • Sophie PERRIAT, PhamD, PhD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06275334
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Feb 23, 2024
Start date
Nov 28, 2023
Primary completion
Nov 2024 (estimated)
Completion
Nov 28, 2024 (estimated)
Last update
Feb 23, 2024

Study contacts

Anne EL AATMANI, Pharm, PhD
Contact
Anne.ELAATMANI@chru-strasbourg.fr
33 3 88 12 78 06

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neuroblastoma→

Other studies from this sponsor

University Hospital, Strasbourg, France

Start the discussion